Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
2020 · Acta Pharmaceutica Sinica B · 139 citations
https://doi.org/10.1016/j.apsb.2020.05.001
H
Haojie Dong
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
5
Papers
233
Citations
5
h-index
4
i10-index
Haojie Dong is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & HER2/EGFR in Cancer Research & Cancer therapeutics and mechanisms. The author has an h-index of 5, co-authored 5 publications.
ORCID: 0000-0002-4502-3340Papers by this author
worksResearch topics
topicsChat about Author
Papers
Chat
Click to start Chat